Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Revenue of Royalty Pharma plc (RPRX)
Revenue in 2023 (TTM): $2.35 B
According to Royalty Pharma plc's latest financial reports the company's current revenue (TTM) is $2.35 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Royalty Pharma plc
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2.35 B | $1.79 B | $1.49 B | $1.7 B | $1.13 B |
| 2022 | $2.24 B | $2.23 B | $983.17 M | $230.06 M | $42.83 M |
| 2021 | $2.29 B | $2.27 B | $1.48 B | $1.24 B | $478.75 M |
| 2020 | $2.12 B | $2.03 B | $1.88 B | $1.7 B | $495.2 M |
| 2019 | $1.81 B | $794.93 M | $2.64 B | $2.46 B | $2.35 B |
| 2018 | $1.79 B | $1.66 B | $1.41 B | $1.52 B | $1.38 B |
| 2017 | $1.6 B | $1.56 B | $1.14 B | $1.34 B | $1.21 B |
| 2016 | $1.88 B | $1.88 B | $791.08 M | $761.9 M | $565.91 M |
| 2015 | $1.65 B | $1.65 B | $862.44 M | $758.71 M | $581.43 M |